Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Fallopian Tube Neoplasms 3Neoplasms 2Leukemia, Myeloid, Acute 2Carcinoma, Ovarian Epithelial 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Sarcoma 1Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Chondrosarcoma 1

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Bevacizumab 8Irinotecan 7Injections 6Cetuximab 6Capecitabine 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5tocilizumab 4pazopanib 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × birinapant × Clear all
NCT02587962 2021-01-14

Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

Medivir

Phase 1/2 Terminated
34 enrolled 27 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡